Paragon 28, Inc. launches the Phantom® Metatarsal Shortening System which features a first in-kind intramedullary device for fixation of in-line shortening osteotomies of lesser metatarsals
Paragon 28, Inc. launches the Phantom® Metatarsal Shortening System which features a first in-kind intramedullary device for fixation of in-line shortening osteotomies of lesser metatarsals
Launch of its Gorilla® Central Column Plating System, offering plates and instrumentation used in isolation for acute or chronic midfoot application or in cases of Charcot.
Muller-Weiss syndrome can require surgery if it progresses far enough along. Weight bearing CT imaging paired with Disior's Bonelogic™ could play a role in detecting early stages of the disease.
With the launch of TenoTac 2.0™, we further refined our initial offering to allow surgeons greater control and precision to address the unique needs of each patient.
Supplemental approval order from the FDA for the Patient Specific Talus Spacer. Allows the Patient Specific Talus Spacer to be additively manufactured in titanium alloy with a titanium nitride coating.
Paragon 28 is pleased to announce the launch of its Silverback™ Mini-Open Plating System to accommodate arthroscopic or mini-open fusion procedures of the ankle.
Paragon 28 is pleased to announce the launch of its ParaDerm® NF Dermal Matrix providing surgeons a structural allograft for applications beneath the skin in cases where additional structural value is desired.
Paragon 28 Announces Addition of B. Kristine Johnson and Kristina Wright to its Board of Directors December 01, 2021 07:00 AM Eastern Standard Time ENGLEWOOD, Colo.–(BUSINESS WIRE)–Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today the appointment of B. Kristine Johnson and...
Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced today that the U.S. Food and Drug Administration (FDA) has given 501(k) marketing clearance to its Circular External Fixation System. The Circular External Fixation System, expected to commercially launch in early 2022, will...
ENGLEWOOD, Colo., Oct. 15, 2021 /PRNewswire/ — Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the pricing of its initial public offering of 7,812,500 shares of its common stock at a public offering price of $16.00 per share, for total gross proceeds of $125.0 million, before deducting underwriting...